Media coverage about Zogenix (NASDAQ:ZGNX) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zogenix earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.9819658470302 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news headlines that may have effected Accern’s scoring:
- Worthy Analytical Review for Zogenix, Inc. (NASDAQ:ZGNX) – The Oracle Examiner (oracleexaminer.com)
- Zogenix Inc. : – Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy (4-traders.com)
- ETFs with exposure to Zogenix, Inc. : October 16, 2017 (finance.yahoo.com)
A number of equities research analysts have recently issued reports on the company. BidaskClub lowered Zogenix from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. ValuEngine lowered Zogenix from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. Zacks Investment Research lowered Zogenix from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Mizuho reiterated a “buy” rating and issued a $51.00 target price (up previously from $28.00) on shares of Zogenix in a research note on Friday, September 29th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $50.00 target price (up previously from $20.00) on shares of Zogenix in a research note on Monday, October 2nd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $40.00.
Shares of Zogenix (NASDAQ ZGNX) opened at 39.00 on Thursday. The firm’s market cap is $968.80 million. The stock has a 50 day moving average price of $23.91 and a 200-day moving average price of $15.50. Zogenix has a 1-year low of $7.50 and a 1-year high of $41.80.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.01). Zogenix had a negative return on equity of 70.75% and a negative net margin of 309.76%. The company had revenue of $7.10 million during the quarter, compared to analyst estimates of $3.48 million. During the same period in the prior year, the firm earned ($0.76) EPS. Zogenix’s quarterly revenue was up 238.1% on a year-over-year basis. On average, equities research analysts expect that Zogenix will post ($3.62) earnings per share for the current fiscal year.
In other Zogenix news, major shareholder Life Sciences Maste Perceptive acquired 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was acquired at an average price of $37.50 per share, with a total value of $11,250,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.00% of the stock is currently owned by insiders.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.